| 摘要 |
<p>The invention is in the field of medical tools and therapies. It provides a cell line and methods for its use. More in particular the invention provides the use of a HLA-A2 positive cell line, derived from human blood, with dendritic cell properties, its potential use as an agent or a vaccine for cancer immunotherapy and the treatment and/or prophylaxis of immune diseases. Furthermore the invention describes the use of these cells as a model system for studying the biology of dendritic cells or dendritic cell/pathogen interactions. More in particular, the invention relates to a human cell or cell line, obtainable from human peripheral blood, with the phenotype: CD3-, CD4-, CD7-, CD163-, CD14-, CD34-, CD56-, CD19+, CD79-, CD11b-, CD11C+, CD1a+, CD40+, CD80+, CD83+, CD86+, HLA-DR+, HLA-DQ+, HLA-ABC+, DC-SIGN-, CD206-, DEC205+, DECTIN-, BDCA2-.</p> |
